Comparison of accompanying proteins in different therapeutic human serum albumin preparations

• Published in: Biologicals Vol. 64; pp. 41 - 48
• Main Authors: Mikkat, Stefan, Dominik, Adrian, Stange, Jan, Eggert, Martin
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2020
• Subjects: Contaminating proteins; Hepalbin adsorbent; Humans; Mass Spectrometry; Oxidation-Reduction; Pharmaceutical Preparations - chemistry; Pharmaceutical Preparations - isolation & purification; Pharmaceutical Preparations - standards; Plasma - chemistry; ProteoMiner; Quality control; Serum Albumin, Human - chemistry; Serum Albumin, Human - isolation & purification; Serum Albumin, Human - standards; Therapeutic human serum albumin; ProteoMiner; Therapeutic human serum albumin; Contaminating proteins; Mass spectrometry; Hepalbin adsorbent; Quality control
• ISSN: 1045-1056; 1095-8320
• DOI: 10.1016/j.biologicals.2020.01.003

Pharmaceutical human serum albumin products are manufactured from donated human plasma and may contain up to 5% accompanying non-albumin proteins. It has been reported that albumin preparations manufactured by different pharmaceutical companies differed in the degree of posttranslational modifications, the redox state as well as antioxidant properties of albumin, whereas the composition of the accompanying proteins has never been comparatively analyzed. In this study, a non-targeted mass spectrometric approach was used for label-free quantification and comparison of different pharmaceutical albumin preparations. Haptoglobin and a few other proteins accounted for approximately 80% of the accompanying proteins in all products tested. Low abundance proteins were enriched by means of a combinatorial peptide ligand library (ProteoMiner, Bio-Rad). Significant differences between the amounts of several mainly low abundance proteins, such as complement factors, were observed indicating differences in the manufacturing processes of the pharmaceutical companies. The removal of the stabilizers octanoate and N-acetyltryptophan from albumin solutions using the charcoal-based Hepalbin adsorbent simultaneously reduced the accompanying proteins. For therapy evaluation of albumin preparations, the variable composition of the accompanying proteins in different albumin products should be taken into account in addition to the known heterogeneity of the albumin protein itself.